Bristol-Myers Squibb Company (BMY)
|Net Income (ttm)||-6.22B|
|Trading Day||May 7|
|Day's Range||64.19 - 65.39|
|52-Week Range||52.43 - 66.93|
FATE reports a wider Q1 loss on increased R&D expenses.
DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) ...
NEW YORK, May 6, 2021 /PRNewswire/ -- DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY). The r...
Quarter was awful, with no upside: Jim Cramer on Bristol Myers earnings
Jim Cramer and Stephanie Link, Hightower, react to Bristol Myers' disappointing earnings and the other names they're looking to instead.
NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
Going by historical performance, there is a 62% chance of a rise in BMY stock over the next month. Out of 116 instances in the last ten years that BMY stock saw a five-day decline of 5.2% or more, 72 of...
Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopa...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at upcoming ACC.21
Investors will have to wait for the full data set to see how much the drug could really help cancer patients.
Abecma is on the market.
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivoluma...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review BMS's Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
The big drugmaker reported disappointing first-quarter results.
Bristol-Myers Squibb Co (NYSE: BMY) joined other drugmakers in missing first-quarter earnings consensus due to a decline in medical visits and new diagnoses as COVID-19 cases surged at the start of the ...
Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.
Part of the problem was the company's strong performance a year ago.
Bristol Myers (BMY) delivered earnings and revenue surprises of -3.33% and -0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Bristol-Myers Squibb (NYSE:BMY) decreased 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 1.16% year over year to $1.74, which misse...
Bristol Myers Squibb Co reported lower-than-expected first-quarter profit on Thursday as sales of its high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.
Bristol Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
BMY vs. HZNP: Which Stock Is the Better Value Option?
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Bristol-Myers Squibb Company's Directors and Officers f...
NEW YORK--(BUSINESS WIRE)-- #BMY--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Bristol-Myers Squibb Company's Directors and Officers for Breach of Fiduciary Duties–BMY
Eli Lilly and Co. (NYSE:LLY) jumped four places from last year to capture the top spot in IDEA Pharma's Pharmaceutical Innovation Index, supplanting the 2020 leader Roche (RHHBY). In the drug consulting...
They're generating revenue now -- and more is on the way.
Not every stock is ridiculously expensive right now.
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2021 results.
European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Roche Holdings AG's (OTCMKTS: RHHBY) Enspryng, AbbVie Inc's (NYSE: AB...
Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque...
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of D...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AADVMX2021--Bristol Myers Squibb Presents Positive Data at AAD
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maint...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AML--BMS Receives Positive CHMP Opinion for Onureg® (azacitidine tablets;CC-486) as Frontline Oral Maintenance Therapy forAdults w AML in First Remission
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimu...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo + Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (BMY) Outperforming Other Medical Stocks This Year?
This undervalued pharmaceutical is a great buy in 2021.
Bristol-Myers Squibb Co (NYSE: BMY) continues to scale its CAR-T operations with the latest move to open its first cell manufacturing site in Europe and fifth worldwide. BMY is set to build a new cell t...
Bristol Myers Squibb (BMY) closed at $65.60 in the latest trading session, marking a +0.21% move from the prior day.
Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Adv...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Opdivo in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer....
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (ca...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Opdivo--BMS Receives EC Approval for Opdivo® (nivolumab) in Comb w Cabometyx® (cabozantinib) as First-Line Treatment for Patients w Advanced Renal Cell Carcin
WALTHAM, Mass.--(BUSINESS WIRE)-- #Dermatology--Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company, today announced two new appointments to its leadership team.
See why the world's most acclaimed value investor is investing in these three stocks.
Key recent clinical pipeline developments have prompted an analyst at Truist Securities to turn bullish on pharma giant Bristol-Myers Squibb Company (NYSE: BMY). The Bristol-Myers Squibb Analyst: Gregg ...
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and ps... [Read more...]
|Stock Exchange |
|Ticker Symbol |
According to 19 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is 75.44, which is an increase of 17.07% from the latest price.